ClinicalTrials.gg
RecruitingNCT07226232PIVOTUpdated Oct 23, 2026

Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression

A Phase 3 interventional study of Psilocybin and Psilocybin in Major Depression, sponsored by VA Office of Research and Development. Recruiting at 5 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by VA Office of Research and Development · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 23, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies testing psilocybin in Depressive Disorder, Major — 11 open to participants now, 16 under way, 4 of them phase 3. Psilocybin · Depressive Disorder, Major.

Planned enrollment
2nd of 31
240 · median 35
Started
2026
with 4 others
Phase 3
4 of 31
3 open now
Primary completion
2030-12
later than 14 of 15 live
Registered
25th of 31
by date
Lead sponsor
2 of 31
VA Office of Research and Development

Among the 31 studies testing psilocybin in Depressive Disorder, Major, this one is the 2nd largest by planned enrollment, is one of 5 that started in 2026, is one of 4 in phase 3, reaches primary completion later than 14 of the 15 other live ones, and was the 25th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

11 of the 31 studies testing psilocybin in Depressive Disorder, Major are open now, in 7 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About psilocybin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing psilocybin in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this multi-site randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of depression in U.S. military Veterans with and without (±) concurrent posttraumatic stress disorder.

Read the detailed description

Treatment-resistant depression (TRD) is a serious mental health problem in Veterans, frequently comorbid with post-traumatic stress disorder (PTSD), and in need of novel and effective treatments. Clinical studies have revealed antidepressant effects of psilocybin for depression in civilians, but less is known about its efficacy and safety in Veterans. Very limited data is available on the effects of psilocybin in the treatment of PTSD. Thus, it is important to evaluate the safety and efficacy of psilocybin in the treatment of TRD with and without PTSD among Veterans.

The purpose of this multi-site, double-blind, randomized controlled trial is to evaluate the efficacy and risks of psilocybin for the treatment of TRD in U.S. military Veterans with and without (±) concurrent PTSD. Eligible and consenting Veterans will two psilocybin dosing sessions along with preparation, administration, and integration psychological support provided by a facilitator. For the 1st psilocybin administration, participants will be randomized to one of two doses under blinded conditions. One month later, all participants will receive the same dose at their 2nd psilocybin visit. Outcomes will be measured by an independent evaluator masked from all treatments at 2 and 4 weeks after each dosing session. Longer-term follow-up will be conducted over 6 months. Both expected and unanticipated adverse events will be collected by type, severity and relatedness to the study drug.

03

Conditions studied

  • Major Depression

Keywords

  • depression
  • psilocybin
  • veterans
  • post-traumatic stress disorder
04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Veteran of the U.S. military who is English-speaking
  • Signed and Health Insurance Portability and Accountability Act (HIPAA)
  • Adults \</= 75 years of age
  • Meets criteria for current major depressive episode (MDE)
  • Montgomery-Asberg Rating Scale (MADRS)>/= 20 at baseline
  • Failure to respond satisfactorily to >/= 2 antidepressant treatments for >/= 8 weeks, including >/= 2 weeks at an adequate dose (>/= 50% of the FDA-approved uppermost dose) for major depression. Augmentation with a medication for depression (e.g., neuroleptics, lithium, levothyroxine) is considered a separate course of treatment.
  • If applicable, concurrent \& permitted antidepressants must be at stable doses for >/= 4 weeks prior to baseline (see allowed \& prohibited medication list)
  • Participants of must have negative pregnancy test \& agree to adhere to a medically acceptable method of during the study
  • Has a responsible adult who will provide transportation to the participant's home or place of lodging on the days of psilocybin administration

Exclusion criteria

Exclusion Criteria:

  • Lifetime bipolar, schizophrenia spectrum, or other psychotic disorders
  • First-degree relative with history of bipolar I, schizophrenia spectrum or other psychotic disorder
  • Presence of psychotic symptoms (e.g., MDE with psychotic symptoms)
  • Sedative-hypnotic, stimulant, inhalant and/or opioid use disorder within past 6 months (lifetime substance use disorder is allowed at the discretion of the LSI)
  • Severe alcohol and/or cannabis use disorder within the past 6 months (mild or moderate alcohol and/or cannabis use is allowed at the discretion of the LSI)
  • Lifetime hallucinogen persisting perception or hallucinogen use disorders
  • Use of psilocybin, ayahuasca, mescaline, lysergic acid diethylamide (LSD), dimethyltryptamine (DMT), 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), peyote, or 3,4-methylenedioxymethamphetamine (MDMA) within past XX months
  • Participant agrees to not use psychedelics (listed above) during the study, except as prescribed by the study protocol
  • Taking prohibited medication within 2 weeks of baseline (see allowed and prohibited concomitant medication list)
  • History of severe traumatic brain injury (TBI)
  • Diagnosis of dementia or related progressive neurocognitive disorder
  • Suicidal ideation/behavior Type 4 or Type 5 intensity on C-SSRS within past 6 months of baseline
  • Psychiatric inpatient treatment within past 3 months of baseline
  • Treatment with electroconvulsive therapy, deep brain stimulation, vagus nerve stimulation, or transcranial magnetic stimulation within 3 months of baseline
  • Implanted central nervous system device
  • Treatment with evidence-based psychotherapy (EBP) for MDD or PTSD within 2 weeks prior to baseline. If receiving EBP therapy, he/she must complete treatment at least 2 weeks prior to baseline. Other forms of non-EBP psychotherapy for MDD or PTSD are allowed to continue during the study period.
  • Pregnancy or lactation, or anticipated pregnancy or breastfeeding during the active treatment phase
  • History of myocardial infarction, congestive heart failure, diabetic ketoacidosis, brain cancer, stroke and/or severe cardiac disease
  • cardiac, pulmonary, renal, liver and/or other medical disease that, in the opinion of the investigator, may contraindicate the use of psilocybin, interfere with the interpretation of study results and/or constitute a health risk for the participant if they take part in the study
  • Seizure disorder, except for seizures due to fever or withdrawal from a substance
  • Clinically significant hypertension (>160/95 mmHg), hypotension (\<90/60 mmHg) tachycardia (>100 bpm at rest), prolongation (>450 msec men; >470 msec women) or clinically significant arrhythmia on
  • Clinically significant abnormal laboratory results on chemistry panel, liver function tests, complete blood count, and/or thyroid stimulating hormone
  • Positive urine drug screen for illicit drugs of abuse (except for THC) at screening or baseline
  • Prior allergic, adverse reaction or adverse experience to a psilocybin formulation
  • Litigating for disability income for a mental disorder outside the VA compensation and pension process
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Active comparator
    Control

    Psilocybin comparator dose

    Drug: Psilocybin

  • Experimental
    Intervention

    Psilocybin intervention dose

    Drug: Psilocybin

Interventions

  • Psilocybin comparator dose

    Also known as: COMP360

  • Psilocybin Intervention Dose

    Also known as: COMP360

06

What researchers measure

Primary outcomes

  1. Montgomery-Asberg Rating Scale (MADRS)

    10-item clinician-administered rating scale for depression. Scored 0 to 60; higher score indicates more severe symptomatology.

    Time frame: 2 weeks

Secondary outcomes

  1. Swiss Psychedelic Side Effects Inventory Overall Score

    A clinician guided self-report form that has a list of effects pertaining to psychedelics; has the option to add other side effects (or expected effects) as desired and includes an open text field to provide additional details that are not captured in the inventory list. In addition to rating severity of the side effects, the SPSI captures impact, causality, timing and duration, and has a global rating on tolerability. Scoring: Calculate total scores for the number of side effects, severity, and impact by adding the relevant columns. Calculate total scores for the number of side effects, severity, and impact by adding the relevant columns. The overall score is calculated by subtracting total severity from total impact. The overall score represents the burden of side effects for that person within the specified timeframe.

    Time frame: one day

Other outcomes

  1. Clinician-Administered PTSD Scale for DSM-5 - Revised

    A 30-item interview used to rate the past-month PTSD severity in those participants diagnosed with PTSD by CAPS-5-R at baseline. Higher score (0 to 200) indicates higher PTSD severity.

    Time frame: one month

  2. Hamilton Depression Rating Scale

    A validated rater-administered measure of depression severity. The 17-item version yields a score of 0 to 50; higher score indicates more severe depression.

    Time frame: two weeks

  3. Patient Health Questionnaire 9

    A 9-item self-report measure designed to characterize severity of depression; has excellent psychometrics, total score range 0 to 27, higher = more severe.

    Time frame: two weeks

  4. PTSD Checklist for DSM-5

    A 20-item self-report of PTSD symptoms; score 0-80; higher=more severe. Only collected in those with PTSD diagnosis at baseline.

    Time frame: one month

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data and a data dictionary will be shared pending required IRB approval, and if needed, a Data Use Agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: At the conclusion of the study after a data repository has been made operational.

Access criteria: De-identified data of those participants who signed informed consent, to include baseline demographics and clinical characteristics, primary outcome measure over time, treatment assignment, secondary safety outcomes, and exploratory outcomes. Data will be available for 6 years after the closure of the main study.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2030, 51 months after the start.

Of 123 phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 36. This study's planned 51 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2025
First posted
Nov 10, 2025
StartActual
Aug 3, 2026
Primary completionEst.
Dec 2, 2030
CompletionEst.
Jun 30, 2031
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedSigned informed consent and Health Insurance Portability and Accountability Act (HIPAA)
  • EditedMontgomery-Asberg Rating Scale (MADRS )>/= 20 at baseline
Oct 23, 2026
Site contacts
Changed at 4 sites. See the sites
Show 4 sites
  • Tuscaloosa VA Medical Center, Tuscaloosa, AL · Tuscaloosa, United StatesContact p•••@va.gov→none listed
  • VA Portland Health Care System, Portland, OR · Portland, United StatesContact •••1205→•••6204Contact c•••@va.gov→none listedContact added a•••@va.gov · •••6204
  • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA · Philadelphia, United StatesContact •••5800→•••5800Contact •••5800→•••5903
  • VA Puget Sound Health Care System Seattle Division, Seattle, WA · Seattle, United StatesContact added •••1337
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedSigned informed consent and Health Insurance Portability and Accountability Act (HIPAA)
    • EditedMontgomery-Asberg Rating Scale (MADRS )>/= 20 at baseline
    Site contacts Changed at 4 sites. See the sites
    Show 4 sites
    • Tuscaloosa VA Medical Center, Tuscaloosa, AL · Tuscaloosa, United StatesContact p•••@va.gov→none listed
    • VA Portland Health Care System, Portland, OR · Portland, United StatesContact •••1205→•••6204Contact c•••@va.gov→none listedContact added a•••@va.gov · •••6204
    • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA · Philadelphia, United StatesContact •••5800→•••5800Contact •••5800→•••5903
    • VA Puget Sound Health Care System Seattle Division, Seattle, WA · Seattle, United StatesContact added •••1337
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07226232
Responsible party
Sponsor
First posted
Nov 10, 2025
Start date
Aug 3, 2026
Primary completion
Dec 2, 2030 (estimated)
Completion
Jun 30, 2031 (estimated)
Last update
Oct 23, 2026

Study contacts

Lori L Davis, MD AB
Contact
lori.davis@va.gov
(205) 554-3819
Anchal Ghera, MS
Contact
anchal.ghera@va.gov
(205) 899-1273
Lori Lynne Davis, MD AB
principal investigator · Birmingham VA Medical Center, Birmingham, AL

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion